SG Americas Securities LLC Makes New $423,000 Investment in IDEAYA Biosciences, Inc. $IDYA

SG Americas Securities LLC acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,117 shares of the company’s stock, valued at approximately $423,000.

Several other hedge funds also recently modified their holdings of IDYA. Fiera Capital Corp boosted its stake in IDEAYA Biosciences by 26.6% during the second quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock worth $32,208,000 after acquiring an additional 322,404 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in shares of IDEAYA Biosciences by 6.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 18,878 shares of the company’s stock worth $397,000 after purchasing an additional 1,191 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of IDEAYA Biosciences by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock valued at $44,424,000 after buying an additional 33,286 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of IDEAYA Biosciences by 39.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock valued at $70,000 after buying an additional 940 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in IDEAYA Biosciences by 17.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,774 shares of the company’s stock valued at $184,000 after buying an additional 1,291 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 1.1%

Shares of NASDAQ:IDYA opened at $35.88 on Friday. The stock has a market cap of $3.15 billion, a PE ratio of -19.29 and a beta of 0.14. The stock’s fifty day simple moving average is $29.85 and its two-hundred day simple moving average is $25.10. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $36.55.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million during the quarter, compared to the consensus estimate of $59.98 million. On average, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on IDYA shares. Stephens reiterated an “overweight” rating and issued a $45.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. The Goldman Sachs Group lifted their price target on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Tuesday, October 21st. New Street Research set a $30.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Guggenheim started coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 18th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, JMP Securities initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, September 4th. They set a “market outperform” rating and a $41.00 price objective for the company. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.40.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.